Nebulized Immunotherapy of Orthotopic Lung Cancer by Mild Magnetothermal–Based Innate Immunity Activations
Angewandte Chemie International Edition · 2025
DOI: 10.1002/anie.202413127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von Lizhu Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Science and Engineering, Institute of Advanced Study, Shanghai Key Laboratory of Chemical Assessment and Sustainability, Shanghai …. Hauptthemen laut MEDLINE: Lung Neoplasms, Immunotherapy, Immunity, Innate. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: the National Key R&D Program of China, the National Natural Science Foundation of China, the Program of Shanghai Academic/ Technology Research Leader.
Abstract (Originalsprache)
Advances in adaptive immunity have greatly contributed to the development of cancer immunotherapy. However, its over‐low efficacy and insufficient invasion of immune cells in the tumor tissue, and safety problems caused by cytokine storm, have seriously impeded further clinical application for solid tumor immunotherapy. Notably, the immune microenvironment of the lungs is naturally enriched with alveolar macrophages (AMs). Herein, we introduce a novel nebulized magnetothermal immunotherapy strategy to treat orthotopic lung cancer by using magnetothermal nanomaterial (Zn−CoFe 2 O 4 @Zn−MnFe 2 O 4 −PEG, named ZCMP), which can release iron ions via an acid/thermal‐catalytic reaction to maximize the use of lung‘s immune environment through the cascade activations of AMs and natural killer (NK) cells. Nebulized administration greatly enhance drug bioavailability by localized drug accumulation at the lesion site. Upon mild magnetic hyperthermia, the released iron ions catalyze endogenous H 2 O 2 decomposition to produce reactive oxygen species (ROS), which triggers the M1 polarization of AMs, and the resultant inflammatory cytokine IFN‐β, IL‐1β and IL‐15 releases to activate c‐Jun, STAT5 and GZMB related signaling pathways, promoting NK cells proliferation and activation. This innovative strategy optimally utilizes the lung‘s immune environment and shows excellent immunotherapeutic outcomes against orthotopic lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Chemical Science and Engineering, Institute of Advanced Study, Shanghai Key Laboratory of Chemical Assessment and Sustainability, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, 200092…
- State Key Laboratory of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 200050, Shanghai, P.R. China.
ORCID-Profile: Jianlin Shi
Förderung
- the National Key R&D Program of China
- the National Natural Science Foundation of China
- the Program of Shanghai Academic/ Technology Research Leader
- the Youth Climbing Plan of Chinese Academy of Sciences
- the Biomedical Orientation Project of Shanghai Science and Technology Commission
- the Fundamental Research Funds for the Central Universities
- the Interdisciplinary Joint Research Project by Tongji University
Zitieren
APA
Chen, L., Hu, P., Fang, W., Wu, T., & Shi, J. (2025). Nebulized Immunotherapy of Orthotopic Lung Cancer by Mild Magnetothermal–Based Innate Immunity Activations. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202413127
Vancouver
Chen L, Hu P, Fang W, Wu T, Shi J. Nebulized Immunotherapy of Orthotopic Lung Cancer by Mild Magnetothermal–Based Innate Immunity Activations. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202413127
BibTeX
@article{Chen2025,
author = {Chen, Lizhu and Hu, Ping and Fang, Wenming and Wu, Tong and Shi, Jianlin},
title = {Nebulized Immunotherapy of Orthotopic Lung Cancer by Mild Magnetothermal–Based Innate Immunity Activations},
journal = {Angewandte Chemie International Edition},
year = {2025},
doi = {10.1002/anie.202413127}
}
EUVIMED